Introduction Atrial fibrillation (AF)-induced cardiomyopathy (AIC) is retrospectively defined after normalisation of left ...

A potentially life-changing heart condition, dilated cardiomyopathy, can be caused by the cumulative influence of hundreds or ...

Gene therapy for Danon disease, a rare inherited cause of hypertrophic cardiomyopathy, appeared to improve or stabilize the ...

The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.A recent comprehensive analysis has projected a significant ...

Background Fabry disease (FD) causes multiorgan sphingolipid accumulation, with cardiac involvement responsible for the ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...

Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.

The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...

But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

Secretome Therapeutics Inc. has closed a $20.4 million round of financing to support its development of therapies derived from neonatal cardiac progenitor cells.